Legend Biotech (NASDAQ: LEGN) CEO lifts direct stake 1.8% in share purchase

What happened

Ingrid Zhang bought 20,000 ordinary shares of Legend Biotech Corp (NASDAQ: LEGN), increasing the chief executive officer's direct ownership. The trade matters to holders tracking insider ownership because it adds to an existing stake rather than starting a new one.

Zhang made the purchase on Nov. 17 at $8.16 per ordinary share, for a total of about $163,200. That outlay bought the additional shares and is separate from the value of the full position.

The transaction was priced in American Depositary Shares at $16.32 each. Each American Depositary Share represents two ordinary shares, so the lower price in the filing is a conversion to the underlying share price, not the price of a separate trade.

The Form 4, signed Nov. 20, puts Zhang's direct holding at 1,151,860 ordinary shares after the purchase. The filing uses ordinary shares for both the amount acquired and the resulting position, putting the two share counts on the same basis.

Key numbers

Metric Latest Change Source
Shares purchased 20,000 ordinary shares SEC Form 4
Purchase price per ordinary share $8.16 per ordinary share SEC Form 4
Total purchase value about $163,200 SEC Form 4
Direct holding after purchase 1,151,860 ordinary shares SEC Form 4
Purchase price per American Depositary Share $16.32 per American Depositary Share SEC Form 4

Read more: Legend Biotech (LEGN) company research

Why it matters

Measured against Zhang's prior holding, the purchase was a small addition. It amounted to 1.8% of the 1,131,860 ordinary shares Zhang held immediately before the trade, OptimistFi calculates. That percentage measures the growth in Zhang's own position, not Zhang's ownership as a percentage of the company.

The distinction from a stock award is that Zhang paid for the added shares. The acquired securities were non-derivative shares, so the purchase added exposure through ownership rather than through a right to buy shares later. The purchase therefore increased the number of shares through which the CEO participates in gains or losses in the stock.

OptimistFi has argued that the investment case depends on the company turning product adoption into durable profits. Zhang's purchase leaves that view unchanged because a single insider trade does not establish that adoption or profitability is improving.

Stock perps: every US stock that trades as a perpetual future, by leverage, live

What's next

In the next quarterly report, evidence that product adoption is translating into higher profits would support OptimistFi's view of the company's path to sustained profitability.

More from OptimistFi

From OptimistFi Perps

Sources

  • SEC Form 4 — Zhang's Nov. 17 purchase, the ordinary share and depositary share prices, and the direct holding after the trade.

Explore OptimistFi research on Legend Biotech Corp: https://optimistfi.com/stocks/LEGN

Browse Legend Biotech Corp company coverage and explore the OptimistFi Thesis-Break Engine.

Browse every company OptimistFi covers at optimistfi.com/stocks, or read the latest evidence-first research.

Find available research on the Legend Biotech Corp company page.

Originally published on OptimistFi, evidence-first equity research. More at optimistfi.com.